In cytokine profiling array to screen the biomarkers, a comparison of one aGVHD patient with another no GVHD patient could increase the risk of selecting the wrong marker (such as β2-MG, PF-4, and TNFSF-14) and missing the best biomarker for GVHD. This evidence concerns the gene TNFSF14 and graft versus host disease.